macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients ...

D Molecular Therapeutics (NASDAQ:FDMT) achieves FDA RMAT status for 4D-150 as a diabetic macular edema treatment, backed by ...

A single intravitreal injection of UBX1325 (foselutoclax) was shown to be safe in patients with diabetic macular edema. The ...

D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and ...

According to a study published in the National Center for Biotechnology Information, the prevalence of macular edema is anywhere from 4.2% to 7.9% in patients with type 1 diabetes and 1.4% to 12.8% in ...

A single intravitreal injection of UBX1325 (foselutoclax) was shown to be safe in patients with diabetic macular edema. The drug also showed potential efficacy in patients who failed to optimally ...

Patients with diabetic macular edema treated with intravitreal aflibercept have a significantly higher risk of adverse renal events compared with those treated with ranibizumab.

What Is Diabetic Macular Edema (DME)? When you have diabetes, you have a lot to manage. High blood sugar can lead to other conditions, like eye problems. One of the most common ones is diabetic ...